11![SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Di SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Di](https://www.pdfsearch.io/img/b52e7c5e5494f1b42754c65dc1206914.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-10-09 07:26:12
|
---|
12![SYNAGEVA BIOPHARMA™ ANNOUNCES SATELLITE SYMPOSIUM AT THE NATIONAL LIPID ASSOCIATION MEETING LEXINGTON, Mass., May 2, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing the SYNAGEVA BIOPHARMA™ ANNOUNCES SATELLITE SYMPOSIUM AT THE NATIONAL LIPID ASSOCIATION MEETING LEXINGTON, Mass., May 2, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing the](https://www.pdfsearch.io/img/50cb712058f84aadd9bb5c3f7776ffc0.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-05-02 07:29:47
|
---|
13![LAL DEFICIENCY DISEASE REVIEW PUBLISHED IN ATHEROSCLEROSIS LEXINGTON, Mass., April 21, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare dise LAL DEFICIENCY DISEASE REVIEW PUBLISHED IN ATHEROSCLEROSIS LEXINGTON, Mass., April 21, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare dise](https://www.pdfsearch.io/img/2d52112d54147b079e7e23e0c03d8f25.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-04-21 08:00:38
|
---|
14![SYNAGEVA’S SEBELIPASE ALFA RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR EARLY ONSET LAL DEFICIENCY FROM THE U.S. FOOD AND DRUG ADMINISTRATION LEXINGTON, Mass., May 20, [removed]Synageva BioPharma Corp. (Synageva) (NASD SYNAGEVA’S SEBELIPASE ALFA RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR EARLY ONSET LAL DEFICIENCY FROM THE U.S. FOOD AND DRUG ADMINISTRATION LEXINGTON, Mass., May 20, [removed]Synageva BioPharma Corp. (Synageva) (NASD](https://www.pdfsearch.io/img/0b92a8900d166c909931964a3ca783f8.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2013-05-20 07:13:10
|
---|
15![SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA AT THE NASPGHAN MEETING LEXINGTON, Mass., October 11, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA AT THE NASPGHAN MEETING LEXINGTON, Mass., October 11, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare](https://www.pdfsearch.io/img/1b6460bb2df43d5f5c653ca9ad20154e.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2013-10-11 07:24:04
|
---|
16![SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA PRESENTATIONS AND SATELLITE SYMPOSIUM AT THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONGRESS LEXINGTON, Mass., June 3, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharm SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA PRESENTATIONS AND SATELLITE SYMPOSIUM AT THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONGRESS LEXINGTON, Mass., June 3, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharm](https://www.pdfsearch.io/img/598fa994f3597d58a54f2098bc140ee1.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-06-03 10:39:51
|
---|
17![Chair Rohit Kohli, MBBS, MS Associate Professor of Pediatrics Medical Director, Complex Surgery and Transplant Inpatient Unit Co-Director, Steatohepatitis Center Chair Rohit Kohli, MBBS, MS Associate Professor of Pediatrics Medical Director, Complex Surgery and Transplant Inpatient Unit Co-Director, Steatohepatitis Center](https://www.pdfsearch.io/img/ab561909e22e164d489f21bf98c05588.jpg) | Add to Reading ListSource URL: www.naspghan.orgLanguage: English - Date: 2014-06-18 09:22:16
|
---|
18![The people. Their lives. The impact[removed]Annual Report
Dear Fellow Shareholders, 2013 was an amazing year for both Synageva and for patients. We met, The people. Their lives. The impact[removed]Annual Report
Dear Fellow Shareholders, 2013 was an amazing year for both Synageva and for patients. We met,](https://www.pdfsearch.io/img/94ba44cc6de9916b25675d1c615534b4.jpg) | Add to Reading ListSource URL: www.synageva.comLanguage: English - Date: 2014-04-23 16:54:16
|
---|
19![Chair Rohit Kohli, MBBS, MS Associate Professor of Pediatrics Medical Director, Complex Surgery and Transplant Inpatient Unit Co-Director, Steatohepatitis Center Chair Rohit Kohli, MBBS, MS Associate Professor of Pediatrics Medical Director, Complex Surgery and Transplant Inpatient Unit Co-Director, Steatohepatitis Center](https://www.pdfsearch.io/img/1338292ab946ef437729618984eb21e8.jpg) | Add to Reading ListSource URL: www.naspghan.orgLanguage: English - Date: 2014-06-27 11:01:50
|
---|